Mounjaro, a popular weight loss and diabetes drug containing tirzepatide, has become the second highest-selling pharmaceutical brand in India, reflecting the nation's growing demand for effective obesity treatments. It recorded ₹80 crore in sales in September, trailing only behind Augmentin. Experts say the surge is due to India's obesity rates, diabetes, and lifestyle-related health issues.